Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference
Aclaris Therapeutics (NASDAQ:ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory diseases, will deliver a corporate presentation at the H.C. Wainwright Inflammation & Immunology Virtual Conference. The presentation is scheduled for Monday, June 30, 2025 at 11:30 AM EDT.
Investors and interested parties can access both the live and archived versions of the presentation through the Events page on the company's website, where it will remain available for a minimum of 30 days.
Aclaris Therapeutics (NASDAQ:ACRS), un'azienda biofarmaceutica in fase clinica specializzata nelle malattie immuno-infiammatorie, terrà una presentazione aziendale alla Conferenza Virtuale H.C. Wainwright su Infiammazione e Immunologia. La presentazione è programmata per lunedì 30 giugno 2025 alle 11:30 EDT.
Investitori e soggetti interessati potranno accedere sia alla diretta che alla versione registrata della presentazione tramite la pagina Eventi del sito web dell'azienda, dove rimarrà disponibile per almeno 30 giorni.
Aclaris Therapeutics (NASDAQ:ACRS), una empresa biofarmacéutica en etapa clínica especializada en enfermedades inmuno-inflamatorias, realizará una presentación corporativa en la Conferencia Virtual de Inflamación e Inmunología H.C. Wainwright. La presentación está programada para el lunes 30 de junio de 2025 a las 11:30 AM EDT.
Los inversores y partes interesadas podrán acceder tanto a la transmisión en vivo como a la versión archivada de la presentación a través de la página de Eventos en el sitio web de la empresa, donde estará disponible por un mínimo de 30 días.
Aclaris Therapeutics (NASDAQ:ACRS)는 면역염증 질환을 전문으로 하는 임상 단계의 생명공학 제약 회사로서, H.C. Wainwright 염증 및 면역학 가상 컨퍼런스에서 기업 발표를 진행할 예정입니다. 발표 일정은 2025년 6월 30일 월요일 오전 11시 30분 EDT입니다.
투자자 및 관심 있는 분들은 회사 웹사이트의 이벤트 페이지를 통해 발표의 생중계 및 녹화본에 접근할 수 있으며, 최소 30일간 이용 가능합니다.
Aclaris Therapeutics (NASDAQ:ACRS), une société biopharmaceutique en phase clinique spécialisée dans les maladies immuno-inflammatoires, présentera une conférence d'entreprise lors de la Conférence Virtuelle H.C. Wainwright sur l'Inflammation et l'Immunologie. La présentation est prévue pour le lundi 30 juin 2025 à 11h30 EDT.
Les investisseurs et les parties intéressées pourront accéder à la fois à la version en direct et à l'enregistrement de la présentation via la page Événements du site web de la société, où elle restera disponible pendant au moins 30 jours.
Aclaris Therapeutics (NASDAQ:ACRS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf immun-inflammatorische Erkrankungen spezialisiert hat, wird eine Unternehmenspräsentation auf der H.C. Wainwright Inflammation & Immunology Virtual Conference halten. Die Präsentation ist für Montag, den 30. Juni 2025 um 11:30 Uhr EDT angesetzt.
Investoren und Interessierte können sowohl die Live- als auch die aufgezeichnete Version der Präsentation über die Veranstaltungsseite auf der Website des Unternehmens abrufen, wo sie mindestens 30 Tage lang verfügbar sein wird.
- None.
- None.
WAYNE, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide a corporate presentation during the H.C. Wainwright Inflammation & Immunology Virtual Conference. The presentation will take place on Monday, June 30, 2025 at 11:30 AM EDT.
A live and archived webcast of the presentation will be accessible on the Events page of https://www.aclaristx.com/. The webcast will be available on the Aclaris website for at least 30 days.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on X (formerly Twitter) at @AclarisTx and on LinkedIn.
Aclaris Therapeutics Contact:
Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com
FAQ
When is Aclaris Therapeutics (ACRS) presenting at the H.C. Wainwright Conference?
How can investors access the Aclaris Therapeutics (ACRS) conference presentation?
How long will the Aclaris Therapeutics (ACRS) presentation recording be available?
What is the focus of Aclaris Therapeutics (ACRS) as a company?
